Lilly anticipates significant 2026 revenue, explores breast cancer combinations

Eli Lilly and Company has set ambitious revenue targets, expecting to achieve as much as $87 billion in sales by 2026. This significant projection has led some market observers to suggest that the company's stock may still be undervalued, even with its current market performance.

In parallel with its financial forecasting, Lilly is actively advancing its oncology pipeline. Reports indicate a new clinical trial collaboration and supply agreement with Prelude Therapeutics. This partnership will assess Prelude's selective degrader, PRT13722, in combination with Lilly's own treatments, Verzenio® and Inluriyo®, for patients with HR+/HER2- breast cancer.

The combination therapy aims to explore novel treatment approaches for a specific subtype of breast cancer. The agreement underscores Lilly's commitment to expanding its portfolio of cancer therapies and investigating synergistic effects of drug combinations.

Further discussions in the market are also considering the possibility of a stock split for Eli Lilly before the end of 2026. While speculative, such a move could impact stock accessibility and trading dynamics. The broader biotechnology sector is also being eyed for potential mergers and acquisitions activity as the year progresses, though specific implications for Lilly were not detailed in today's coverage.